--- title: Reimbursement Strategy for Medical Devices in Europe description: A startup guide to reimbursement strategy for medical devices in Europe: why CE mark is not enough, how HTA works, and how to sequence markets. authors: Tibor Zechmeister, Felix Lenhard category: Funding, Business Models & Reimbursement primary_keyword: reimbursement strategy medical devices Europe startup canonical_url: https://zechmeister-solutions.com/en/blog/reimbursement-strategy-europe-startup-guide source: zechmeister-solutions.com license: All rights reserved. Content may be cited with attribution and a link to the canonical URL. --- # Reimbursement Strategy for Medical Devices in Europe *By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.* > **Reimbursement strategy for medical devices in Europe is not a single strategy. It is a country-by-country sequencing problem. A CE mark is legally necessary to sell in the EU, but it does not put money in your account. Payers in each country decide separately whether your device gets paid for, under what code, and at what price.** **By Tibor Zechmeister and Felix Lenhard.** ## TL;DR - A CE mark under MDR is a market access prerequisite. It is not a reimbursement decision, and treating the two as the same is the most common strategic mistake European MedTech founders make. - Reimbursement in Europe is national. Germany, France, Italy, Spain, Netherlands, Austria, and the Nordics each have their own health technology assessment bodies, pathways, and evidence demands. - Payer evidence demands frequently exceed what MDR Article 61 considers sufficient clinical evidence. Comparative effectiveness, cost-effectiveness, and real-world outcomes are typical asks. - A good startup reimbursement plan starts at the same time as the clinical evaluation plan, so that the clinical evaluation report under MDR Annex XIV and the HTA dossier can share evidence. - Market sequencing is the lever that separates startups that survive the first twenty-four post-CE months from those that do not. **By Tibor Zechmeister and Felix Lenhard.** ## Why this matters An early-stage MedTech founder finishes the conformity assessment, gets the CE mark, and assumes the hard part is done. The product is legal. The market is 450 million people. The sales pipeline can now start. Three months later the founder discovers that in Germany the device needs a DiGA listing or a NUB application or an inclusion in the DRG system to get paid. In France it needs LPPR listing and CNEDIMTS evaluation. In Italy it needs regional tender inclusion. In the Netherlands it needs a positive position from Zorginstituut Nederland. In Spain it needs national or regional evaluation depending on the device. Each of these processes has its own evidence demands, its own timeline, and its own gatekeepers. None of them accept the CE mark as the decision. That gap between regulatory approval and paid-for product is where most European MedTech commercial plans break. The CE mark opens the door to a hallway of payer doors, not to a room full of customers. ## What MDR actually says about evidence — and where payers go further MDR Article 61 and Annex XIV define the clinical evaluation framework. The manufacturer must establish a clinical evaluation plan, collect clinical data, appraise it, and write a clinical evaluation report demonstrating conformity with the general safety and performance requirements. For startups this typically means a structured literature review, data from any clinical investigation the manufacturer conducted under MDR Chapter VI, and post-market follow-up data as it becomes available. The level of clinical evidence considered "sufficient" under MDR Article 61 is a conformity question. It asks whether the device is safe and performs as intended for its intended purpose. It does not ask whether the device is better than the comparator, cheaper than the standard of care, or cost-effective for a national health system. Payers ask all of those other questions. A health technology assessment body in France, Germany, or the UK will want comparative effectiveness data against the current standard of care, a cost-effectiveness model with incremental cost per quality-adjusted life year or a comparable metric, real-world evidence where relevant, and a budget impact analysis. Those requirements go beyond MDR conformity and are where startups under-plan their clinical and economic data. The mismatch is not a flaw in MDR. It is a feature of having two different questions — is this device safe and does it work, and should a public payer pay for it — answered by two different systems. The startup has to serve both. ## A worked example A Class IIa digital therapeutics startup finishes a small single-arm clinical investigation with 80 patients under EN ISO 14155:2020+A11:2024. The data is clean, the safety profile is good, the clinical evaluation report passes notified body review, and the CE mark issues. The founders plan to launch in Germany first because the DiGA fast-track pathway under the German Digital Healthcare Act is the most accessible reimbursement route for a digital therapeutic in Europe. The BfArM DiGA process requires a positive evidence demonstration of a positive healthcare effect, typically through a randomised controlled trial or a comparable design. The single-arm investigation that supported the CE mark does not meet the DiGA evidence bar. The founders now have a choice. Run a second study specifically designed for DiGA evidence — which takes twelve to eighteen months and another round of funding — or launch in a different country first where the evidence demands align better with what they already have, and use the first twelve months of post-market follow-up to generate the comparative data needed for DiGA. If they had built the clinical evaluation plan and the reimbursement plan together from the start, the original 80-patient investigation could have been a two-arm design with the comparator payers wanted to see. The same calendar, the same cost, and the data would have served both the CE mark and the DiGA submission. The gap is not a clinical failure. It is a planning failure. ## The Subtract to Ship playbook **Start the reimbursement plan the day you start the clinical evaluation plan.** The clinical evaluation plan under MDR Annex XIV Part A and the reimbursement strategy are two outputs of the same underlying evidence question. If you plan them separately, you will generate evidence twice. If you plan them together, one dataset can serve both. **Pick two target countries, not five.** Every country added to the initial launch plan roughly doubles the regulatory affairs, market access, and reimbursement workload for the first eighteen months. Pick the two where your device has the clearest pathway and the most aligned evidence demands, and treat everything else as phase two. **Build the HTA-aware clinical investigation.** If you need a clinical investigation for CE mark purposes under MDR Chapter VI, use that investigation to generate the data the target country's HTA body will want. That usually means a comparator arm, patient-reported outcome measures, and outcomes tied to cost drivers in the health system. A single-arm study that serves only the CE mark is a missed opportunity. **Map the gatekeeper in each target country.** Germany: BfArM for DiGA, G-BA and InEK for DRG and NUB. France: HAS and its CNEDIMTS commission for LPPR. England: NICE and NHS Supply Chain. Italy: AIFA for drugs, regional tenders for devices. Each has a defined process, a defined dossier format, and a defined evidence bar. Write the gatekeeper's name on the plan. **Size the reimbursement timeline honestly.** A realistic HTA submission to decision cycle is nine to eighteen months in most European systems, and that is after you have the CE mark and after you have generated the evidence the HTA body wants. If your financial model assumes revenue in the first quarter after CE mark in a country that requires HTA approval, the model is wrong. **Treat private pay and out-of-pocket as a legitimate bridge, not a failure.** For some device categories, self-pay or private insurance coverage during the HTA process is a realistic revenue source. It is not a long-term strategy, but it can bridge the gap between CE mark and public reimbursement. **Carry a reimbursement advisor the way you carry a regulatory advisor.** You do not need a full-time market access hire at seed stage, but you do need someone who has done HTA dossiers in your target countries, who can review your clinical evaluation plan, and who can tell you when the evidence you are generating will not meet the payer bar. Hire them part-time before you run the clinical investigation, not after. ## Reality Check 1. Which two European countries are you launching in first, and what is the specific reimbursement pathway in each? 2. Who is the gatekeeper for reimbursement in each of those countries, and have you read the actual dossier template they require? 3. Does your clinical evaluation plan under MDR Annex XIV generate the data the HTA bodies in your target countries will ask for, or only the data the notified body will ask for? 4. If you need a clinical investigation, does it have a comparator arm aligned with the standard of care the HTA body will ask you to compete against? 5. What is your realistic time from CE mark to first reimbursed sale in each target country, and does your financial model reflect it? 6. Do you have a reimbursement advisor on the team or as a consultant, and have they reviewed the clinical evaluation plan? 7. What is your private-pay or bridge-revenue plan for the months between CE mark and positive HTA decision? ## Frequently Asked Questions **Is there a single European reimbursement pathway?** No. The EU HTA Regulation has introduced joint clinical assessments for some high-risk devices, but pricing and reimbursement remain national competences. Every country decides separately what it pays for and at what price. **Can my CE mark clinical evidence be reused for HTA submissions?** Partly. The clinical data supporting the CE mark is a starting point, but HTA bodies typically want comparative effectiveness and cost-effectiveness data that goes beyond what MDR Article 61 requires. Plan the evidence once, serve both audiences. **Which European country is easiest for reimbursement?** "Easiest" depends on device type. Germany is often attractive for digital therapeutics through DiGA, France has structured device pathways through LPPR and CNEDIMTS, and the UK has NICE. There is no universal easy answer, which is why market sequencing matters. **How long does European reimbursement take after CE mark?** Typically nine to eighteen months per country for devices requiring HTA assessment. Some pathways are faster, some are slower, and almost none are as fast as founders hope. **Do I need a local partner or distributor to get reimbursed?** Not always, but in many markets a local presence — own sales team, local distributor, or local reference site — is part of how the device becomes known to the people who make reimbursement decisions. **Is private-pay a realistic strategy while waiting for reimbursement?** For some device categories yes, particularly in digital health and consumer-adjacent segments. For hospital-based devices private pay is rarely a meaningful revenue source. The answer depends on your device and your customer. ## Related reading - [Health Insurance Reimbursement in Europe](/blog/health-insurance-reimbursement-europe) — the payer landscape in plain language. - [German Reimbursement for Medical Devices](/blog/german-reimbursement-medical-devices) — the DiGA, DRG, and NUB pathways explained. - [French Reimbursement: LPPR and CNEDIMTS](/blog/french-reimbursement-lppr-cnedimts) — the French national framework in detail. - [HTA Submissions for Medical Devices](/blog/hta-submissions-medical-devices) — how health technology assessment dossiers work. - [MDR Article 61: Clinical Evidence Requirements for Startups](/blog/mdr-article-61-clinical-evidence-requirements-startups) — the regulatory evidence baseline that your HTA plan has to exceed. ## Sources 1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 61 (Clinical evaluation), Annex XIV Part A (Clinical evaluation), Chapter VI (Clinical investigations). 2. Regulation (EU) 2021/2282 on health technology assessment. 3. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice. --- *This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*